Literature DB >> 30638600

Allopurinol-Induced Stevens-Johnson Syndrome.

Sushilkumar Satish Gupta1, Nitin Sabharwal2, Ravikaran Patti3, Yizhak Kupfer4.   

Abstract

Allopurinol is a first line agent in treating gout, but it also carries the risk of severe side effects. Stevens-Johnson syndrome (SJS) is one of the life threatening severe cutaneous adverse reactions caused by allopurinol. The severity of the severe cutaneous adverse reactions can be categorized based upon the area of skin involvement: (1) erythema multiforme major limited to 1-2 % of the body surface area (BSA); (2) SJS involving <10% of the BSA, (3) SJS and toxic epidermal necrolysis overlap involving 10-30% of the BSA and (4) toxic epidermal necrolysis syndrome involving >30% of the BSA. SJS can be caused by drugs and viruses, the former being more frequent. We report a case of an 85-year-old Han-Chinese female who developed SJS after ingestion of allopurinol 8 days prior to the hospitalization. The patient also had concomitant acute viral illness, which complicated the clinical scenario causing acute renal failure and hemodynamic compromise.
Copyright © 2018 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allopurinol; Severe cutaneous adverse reactions; Stevens-Johnson syndrome

Year:  2018        PMID: 30638600     DOI: 10.1016/j.amjms.2018.11.018

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  2 in total

1.  Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy.

Authors:  Cristina Scavone; Cristina Di Mauro; Rosanna Ruggiero; Francesca Futura Bernardi; Ugo Trama; Maria Luisa Aiezza; Concetta Rafaniello; Annalisa Capuano
Journal:  Drugs Real World Outcomes       Date:  2020-03

2.  Case report: Alpelisib-induced Stevens-Johnson syndrome.

Authors:  Christine Jane Kurian; Akshay Desai; William Rafferty; Ahmed Kamel Abou Hussein
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.